Oncobiologics Announces Successful Clinical Trial for IBD Treatment

Oncobiologics Announces Successful Clinical Trial for IBD Treatment
shutterstock_116470885Biopharmaceutical company Oncobiologics, Inc. recently announced that its product ONS-3010, an adalimumab (Humira®) biosimilar candidate, has met the primary endpoints in its first clinical trial. ONS-3010 was developed as a biosimilar of adalimumab, which is an injectable, synthetic (man-made) anti-TNF-alpha monoclonal antibody that binds to TNF (tumor necrosis factor) and blocks inflammation. This drug has been approved in several countries for the treatment of inflammatory conditions, such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn’s disease, among others. ONS-3010 from Oncobiologics has the same amino acid sequence as adalimumab, identical pharmaceutical dosage scheme and strength, though its formulation has a different composition. In this first clinical trial, healthy volunteers were enrolled in a 3-arm single-dose pharmacokinetic (PK) study for a comparison between the ONS-3010 and the US- and
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *